Latest 8-K filings

Vireo Growth Inc. announced robust second-quarter 2026 financial results, showcasing substantial year-over-year revenue growth fueled by strategic acquisitions and detailing plans for further expansion.

Hemab Therapeutics announced strong Q2 2026 results with significant pipeline progress, including new data for HMB-002 and HMB-003, and advancement of sutacimig towards Phase 3 trials, bolstered by a substantial cash position post-IPO.

CVRx, Inc. announced the departure of its Chief Revenue Officer, Robert John, and the appointment of Paul Verrastro as Interim Head of Sales.

Beyond Meat has announced a 1-for-30 reverse stock split, effective August 13, 2026, to regain compliance with Nasdaq's minimum bid price requirement.

Immunic, Inc. announced the appointment of Elena Ridloff to its Board of Directors and provided an update on its Phase 3 trials for vidofludimus calcium in multiple sclerosis, with top-line data expected by year-end.

DPC Holdings PLC announced record second quarter 2026 revenue of $269 million, up 34% year-over-year, and initiated full-year guidance.

Xtant Medical Holdings, Inc. announced its second quarter 2026 financial results, reporting a significant decrease in revenue and a net loss, attributed to asset sales and changes in reimbursement.

Aura Biosciences announced Q2 2026 results, a strategic shift to ocular oncology, workforce reduction, and key leadership appointments, extending cash runway to 1H 2029.

908 Devices Inc. announced second quarter 2026 financial results, reporting a 23% year-over-year revenue increase and narrowing its Adjusted EBITDA loss, while also raising its full-year revenue guidance.

Upstream Bio reported second quarter 2026 financial results and business updates, highlighting progress in its verekitug development for severe inflammatory respiratory diseases and a cash runway through 2027.

Vestis Corporation reported third quarter 2026 results, showing improved Adjusted EBITDA and Free Cash Flow, leading to an increased full-year outlook.

Chicago Atlantic Real Estate Finance announced its second quarter 2026 financial results, highlighting $59.2 million in gross originations and continued progress on its merger with Chicago Atlantic BDC, Inc.

The Middleby Corporation announced robust second quarter 2026 results, exceeding guidance for revenue and Adjusted EBITDA, completing its Food Processing business spin-off, and raising its full-year 2026 outlook.

Twenty One Capital's CEO, Raphael Zagury, issued a shareholder letter detailing a five-point strategic plan focused on building operating businesses, capital markets capabilities, and a lending business around its significant Bitcoin holdings.

Harvard Bioscience (HBIO) presented an investor overview highlighting strategic debt refinancing, new executive leadership, and a focused strategy on translational science tools, aiming for enhanced financial flexibility and long-term growth.

Broadwind, Inc. announced robust second quarter 2026 financial results, showcasing significant revenue growth and improved profitability driven by a strategic focus on power generation and critical infrastructure markets.

Harvard Bioscience announced second quarter 2026 financial results, reporting an 11% year-over-year revenue increase to $22.7 million and raising its full-year revenue guidance.

Janus International Group announced Q2 2026 financial results, with revenues up 2.4% year-over-year to $233.5 million, but Adjusted EBITDA decreased 18.0% to $40.2 million.

IES Holdings, Inc. announced a definitive agreement to acquire DBM Global Inc., a major structural steel fabricator, for approximately $650 million in cash and stock.

Bioxytran announced encouraging clinical observations in the first patient treated with PLICID, a novel galectin antagonist for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), showing functional improvements without adverse events.

BioXcel Therapeutics has amended its credit agreement, extending the deadline for a material transaction to August 21, 2026, and lowering its minimum liquidity requirement.

Cardinal Infrastructure Group Inc. announced record second quarter 2026 revenue of $226.9 million, an 114% year-over-year increase, and the acquisition of Allied Paving for approximately $120 million.

Green Thumb Industries Inc. announces an amendment to agreements with RYTHM, Inc. that will result in the consolidation of RYTHM into Green Thumb's financial statements starting October 10, 2026.

Kardigan, Inc. announced its second quarter 2026 financial results, detailing progress in its late-stage cardiovascular drug development programs and a robust cash position following its initial public offering.

Rythm, Inc. has amended material definitive agreements with RSLGH, LLC and Vision Management Services, LLC, removing beneficial ownership limitations on convertible notes and warrants, significantly increasing RSLGH's stake.

Shattuck Labs announced strong Q2 2026 financial results, highlighting positive Phase 1 data for SL-325 and a cash runway extending into 2029.

Invesco Ltd. announced preliminary July 31, 2026, assets under management of $2,447.1 billion, a 0.9% decrease from the previous month, primarily due to unfavorable market returns.

Cardinal Health announced a 6% revenue increase to $63.7 billion for Q4 FY26 and provided FY27 non-GAAP EPS guidance projecting 13-15% growth.

Cardinal Health has entered into a new $4.0 billion unsecured revolving credit agreement, replacing previous facilities and enhancing its financial flexibility.

Aramark announced robust third quarter fiscal 2026 results, showcasing a 9% increase in revenue and a 34% rise in GAAP EPS, leading to an upward revision of its full-year organic revenue growth forecast.